US equities |
NVDA $239.07 ▲+0.07% MU $1,047.78 ▼-1.52% SPCX $172.91 ▲+1.06% MRVL $285.56 ▲+5.28% AMD $650.49 ▲+2.97% INTC $113.24 ▼-2.54% AVGO $377.98 ▲+4.27% SNDK $1,656.24 ▼-2.81%
FinancialContent

Absci Corporation - Common Stock (NQ:ABSI)

10.37 -1.16 (-10.06%)
Delayed Quote Updated: 3:43 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Absci Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
News Provided by USA News Group on behalf of MindWalk Holdings Corp. 
From USA News Group
Via GlobeNewswire
News headline image
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic
Experts at the forefront of reproductive medicine, fertility, and translational research will guide the clinical research program for a new therapeutic antibody treatment 
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization
From Absci Corporation
Via GlobeNewswire
News headline image
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs 
From Absci Corporation; Oracle; AMD
Via GlobeNewswire
News headline image
Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia. 
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
From Absci Corporation
Via GlobeNewswire
< Previous 1 2 3 4 Next >